Prism Medico & Pharmacy Limited reported a net loss of ₹5.83 lakh for the first quarter of FY27 (Q1FY27), ending June 30, 2026, compared to a net profit of ₹65.73 lakh in Q1FY26. The Board of Directors approved the unaudited standalone financial results on August 12, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by Garg Mendiratta & Associates, the statutory auditors.

The company recorded zero revenue from operations in Q1FY27, a sharp contrast to the ₹158.87 lakh generated in the same quarter last year and ₹28.14 lakh in the immediately preceding quarter (Q4FY26). Total income for the quarter was ₹9.06 lakh, derived entirely from other income, which rose significantly from ₹0.04 lakh in Q1FY25. This lack of operational revenue highlights a potential pause or seasonal fluctuation in core business activities during the period.

Total expenses for the quarter amounted to ₹14.89 lakh, up from ₹93.84 lakh in Q1FY25 but higher than the ₹40.64 lakh seen in Q4FY26. Employee benefit expenses accounted for ₹1.77 lakh, while other expenses constituted the largest portion at ₹13.02 lakh. Finance costs remained negligible at ₹0.02 lakh, and depreciation and amortization expenses were ₹0.09 lakh. The profit before tax stood at a loss of ₹5.83 lakh, with no current or deferred tax expenses recorded for the quarter.

What the Numbers Show

The most striking feature of the Q1FY27 results is the complete absence of revenue from operations, which had been ₹158.87 lakh in the same quarter last year. While total expenses decreased substantially year-on-year due to lower material consumption (which was nil in both Q1FY27 and Q4FY26), the fixed costs such as employee benefits and other expenses continued to accrue. The shift from a net profit position in Q1FY26 to a net loss in Q1FY27 underscores the impact of the revenue gap. Additionally, paid-up equity share capital increased to ₹1,356.34 lakh from ₹606.34 lakh in previous periods, indicating a recent capital raise or bonus issue that has not yet translated into operational revenue generation in this quarter.

Prism Medico & Pharmacy Limited has confirmed to stock exchanges that its corporate website is updated and operational, ensuring adherence to regulatory disclosure norms. The company notified the Bombay Stock Exchange (BSE) and the Metropolitan Stock Exchange of India Limited (MSEI) on July 30, 2026, stating that the platform meets the requirements of Regulation 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This update guarantees that investors and stakeholders have continuous access to mandatory information hosted on the company’s digital infrastructure. The move reinforces the firm's commitment to transparency and timely dissemination of material information to the market.

The notification was issued by Davender Singh, Director of Prism Medico & Pharmacy Limited, carrying DIN 09447213. The communication was directed to the Department of Corporate Services at BSE Limited in Mumbai and the Listing Department at MSEI in Mumbai. The company provided the specific web address https://www.prismmedico.in for record-keeping purposes and requested both exchanges to acknowledge receipt of the undertaking.

Regulation 46 mandates listed entities to maintain a dedicated section on their websites for publishing all disclosures required under the SEBI LODR Regulations. By certifying that the website is functional, Prism Medico & Pharmacy Limited affirms that it has no technical barriers preventing investors from accessing annual reports, financial results, board meeting notices, or other statutory filings. This compliance step is routine but critical for maintaining listing status and avoiding regulatory scrutiny regarding information accessibility.

Compliance Details

The following table outlines the key details of the regulatory communication submitted by the company:

Regulatory Context

SEBI’s Listing Obligations and Disclosure Requirements emphasize the importance of digital accessibility for investor protection. Regulation 46 specifically requires listed companies to publish all disclosures on their websites within prescribed timelines. A non-functional or outdated website can lead to penalties or adverse remarks from regulators during inspections. By proactively informing the exchanges, Prism Medico & Pharmacy Limited demonstrates adherence to these governance standards. The company’s registered office is located at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.